Skip to content
‹ Back to IndustriesSciences

How Are AI Pros Weighing ChatGPT’s Role in the World of Science?

New evolving and fast-developing AIs have started rising to fame in recent years, and with the recent invention of ChatGPT – an AI chatbot launched in late 2022 which gained over 100 million users within the first two months of launching – people from all around the world are starting to question the role of AI technology…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By carey.scott · · AiChat GptDeveloping AiScience
Share

Key takeaways

01

New evolving and fast-developing AIs have started rising to fame in recent years, and with the recent invention of ChatGPT – an AI chatbot launched in late 2022 which gained over 100 million users within the first two months of launching – people from all around the world are starting to question the role of AI technology…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

New evolving and fast-developing AIs have started rising to fame in recent years, and with the recent invention of ChatGPT – an AI chatbot launched in late 2022 which gained over 100 million users within the first two months of launching – people from all around the world are starting to question the role of AI technology in their daily lives. Among these uncertainties is ChatGPT’s role in the world of science.

Will there be a huge impact of ChatGPT and developing AI in science? How will Chat GPT and developing AI contribute to modern science?

Biologists like Casey Greene and Milton Pividori see the tool as incredibly useful. After running their own research of using the tool for improving the quality and readability of academic manuscripts, Pividori concluded that ChatGPT, alongside other AI tools, is adding value to their lives by making helping scientists be “more productive as researchers.”

Meanwhile, other scientists are saying that they now regularly use LLMs (large language models like ChatGPT) not only to edit manuscripts but also to help them write or check code and to brainstorm ideas. As Nature.com reports, scientists like Almira Osmanovic Thunström, a neurobiologist at Sahlgrenska University Hospital in Gothenburg, says the use of ChatGPT will keep scientists from needing to “sit and write long introductions for grant applications.”

That being said, many scientists and researchers have pointed out a few disadvantages of AI tools. These are in the form of inaccurate information and fictitious citations presented by AI machines, giving scientists a reason to rely less on AI and more on their own manual research and cross-referencing. Can researchers confidently pinpoint ChatGPT’s role in the world of science?

Ganesh Gopalan, CEO and co-founder of Gnani.ai, a conversational AI platform with a focus on customer experience enhancement, weighs in on the impact of ChatGPT and other developing AI tools in the world of science and the difference it can make in research fields.

Ganesh Gopalan’s Thoughts

“ChatGPT is going to help researchers automate all their routine activities such as writing publications, reviewing documents are automatically creating extracts.

These articles typically warn of the pitfalls in terms of biases that ChatGPT could throw up and the possible inaccuracies. So, what I thought the best thing to evaluate this is to ask ChatGPT the same question. When I ask ChatGPT the same questions, I got a lot more results such as the influence on drug discovery, the influence on analyzing large pieces of scientific data and finding the relationships.

So essentially, I guess ChatGPT has a lot of benefits for science but you’ve gotta be a little careful on the biases and also on the accuracy of the data.”

Article written by Azam Saghir.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

C
carey.scott
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Photonic AI hardware is now in outside testers' hands

Photonic AI hardware is now in outside testers' hands

Kopin is expanding microLED manufacturing in Westborough, Massachusetts, which could add up to 80 jobs over five years. Its microLEDs will go to military displays and to Neural I/o, an interconnect that sends AI data as light. In the same news round-up, Q.ANT and IONOS opened a photonic processor pilot where approved applicants can run their own workloads.

  • 01Two photonic approaches tied to AI’s power problem reached testable hardware this month: PsiQuantum’s 8×8 optical switch samples and Q.ANT’s second-generation processor via an IONOS bare-metal pilot in Germany.
  • 02PsiQuantum is sending samples of an 8×8 demonstration optical circuit switch to selected prospective customers, giving buyers hardware they can test even though commercial products and full specs are still pending.
  • 03Staffing may not keep up with demand: a 2023 Applied Optics study projected US demand for 42,000 new middle-skilled photonics workers by 2030, and expansions like Kopin's could draw from that same pool.

Nov 15, 2026

Lilly breaks ground on a $5B Virginia bioconjugate plant and expects its first building to open in 2030

Lilly breaks ground on a $5B Virginia bioconjugate plant and expects its first building to open in 2030

Eli Lilly held a groundbreaking on Oct. 22 for a $5 billion manufacturing plant in Goochland County, Virginia. The company expects the first building to open in 2030. Lilly has also committed $40 million to the Virginia Center for Advanced Pharmaceutical Manufacturing, a statewide workforce development network that brings together industry, government and higher education partners. The network's plans include a pilot-scale training center in Goochland County, slated to open in 2028. That timing could let workers start training before the plant begins production.

  • 01Goochland’s pilot-scale training center is slated to open in 2028, two years before Lilly expects its first production building in 2030—signaling workforce readiness as the earliest milestone at Lilly’s first dedicated, fully integrated API and drug product facility for its bioconjugate platform and monoclonal antibody portfolio.
  • 02For anyone tracking new ADC supply, Goochland is a later story: Lilly expects to open the first building in 2030 and the second in 2031.

Nov 15, 2026

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Andelyn Biosciences will develop and manufacture CLZ002, Celliaz’s investigational AAV2 gene therapy for retinitis pigmentosa, supporting IND-enabling studies and a planned Phase 1/2 trial. CLZ002 targets a retinal repair mechanism rather than specific mutations. If it works as intended, one manufacturing process could serve patients across many genetic causes of the disease.

  • 01Retinitis pigmentosa can arise from mutations in more than 90 genes; CLZ002 targets a retinal repair mechanism, and if it works as intended one AAV2 manufacturing process could serve patients that gene-specific programs would split into many products.
  • 02For a pre-IND sponsor, putting plasmid and viral vector production with one CDMO can mean fewer handoffs, and the questions worth settling early are who owns the process built on a proprietary platform and how it would move if needed.

Nov 14, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

C
carey.scott

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512